| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $267K | — | -83.0% |
| SG&A Expense | $1.2M | — | +94.4% |
| Operating Income | -$2.2M | — | +24.9% |
| Net Income | -$2.2M | — | +29.5% |
| EPS (Basic) | -$0.43 | — | -43.3% |
| EPS (Diluted) | -$0.43 | — | -43.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.1M | +226.3% | -75.8% |
| Current Assets | $2.5M | +389.7% | -50.3% |
| Total Assets | $11.8M | +12.7% | +122.4% |
| Current Liabilities | $8.3M | +4.3% | +366.0% |
| Total Liabilities | $8.5M | +2.9% | +317.9% |
| Stockholders' Equity | $3.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.4M | — | +4.3% |
| Investing Cash Flow | -$36K | — | — |
| Financing Cash Flow | $3.2M | — | -37.3% |
| +1.9% |